Andrew Humberstone

No ORCID on file · 7 papers in corpus · active 2019-2022

Study types

  • article 5
  • other 1
  • rct 1

Condition tags

  • adenomyosis 3
  • endometriosis 3
  • dyspareunia 2
  • dysmenorrhea 2
  • mesh:D017699 1
  • mesh:D004414 1
  • mesh:D004412 1
rct
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials
Lancet (London, England) ·doi:10.1016/S0140-6736(22)01475-1

BACKGROUND: Uterine fibroids are common non-cancerous neoplasm that cause heavy menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone receptor antagonist taken once per day that dose-dependently suppresses…

article 2022
O-306 LINZAGOLIX FOR ENDOMETRIOSIS-ASSOCIATED PAIN: SAFETY RESULTS FROM EDELWEISS 3, A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
·doi:10.1093/humrep/deac105.103

Abstract Study question Is once-daily linzagolix treatment for women with moderate to severe endometriosis-associated pain (EAP) safe for use for up to 6 months of treatment? Summary answer Both doses of linzagolix were well-tolerated with …

other 2022
Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study
Reproductive biomedicine online ·doi:10.1016/j.rbmo.2021.09.019

RESEARCH QUESTION: Does a once-daily regimen of linzagolix, a new oral gonadotrophin-releasing hormone (GnRH) antagonist, given at a fully suppressive dose (200 mg) for 12 weeks, followed by a partially suppressive dose (100 mg) for a furth…

article 2021
EFFICACY AND SAFETY OF LINZAGOLIX FOR THE TREATMENT OF SEVERE ADENOMYOSIS: FINAL Results FROM A PILOT STUDY
·doi:10.1016/j.fertnstert.2021.07.881
article 2021
Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration
Journal of clinical medicine ·doi:10.3390/jcm10245794

(1) Background: The aim of the present pilot study was to study the effect of a new oral gonadotropin-releasing hormone antagonist on adenomyosis. (2) Methods: Eight premenopausal women, aged between 37 and 45 years, presenting with heavy m…

article 2019
Long term treatment of endometriosis associated pain (EAP) with linzagolix: efficacy and safety after 12 months of treatment
·doi:10.1016/j.fertnstert.2019.07.935
article 2019
The Effect of Linzagolix on Bone Mineral Density (BMD): Safety Results From a Dose-Ranging Trial [21J]
·doi:10.1097/01.aog.0000558837.48634.b6

INTRODUCTION: Linzagolix is a new, non-peptide, GnRH receptor antagonist being developed to treat endometriosis-associated pain (EAP). The EDELWEISS trial is a Phase 2b, double-blind, randomized, placebo-controlled, multicenter, dose-rangin…